Bisphosphonates

Lambrinoudaki, Ιrene; Christodoulakos, George; BOTSIS, D.

doi:10.1196/annals.1365.036

Cited by 62 publications

(40 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Alendronate is classified as a bisphosphonate drug, like other medications in this class alendronate inhibits bone resorption via action on osteoclasts or on osteoclast precursors. There are other antiresorptive agent used in treatment of osteoporosis like selective estrogen receptor modulators (SERMS) and calcitonin 3 .…”

Section: H G Eltoukhymentioning

confidence: 99%

Untitled

2016

IJPSR

View full text Add to dashboard Cite

Background:Currently oral bisphosphonates such as alendronate are the preferred therapeutic option for the treatment of postmenopausal osteoporosis by increasing bone mineral density and decreasing both vertebral and non-vertebral fracture risk. Silymarin is mainly used as hepato-protectant but in recent studies on ovariectomized rats, it was found that silymarin can be a promising antiosteoporotic pharmacological agent and selective estrogen receptor modulator. Objective: To evaluate the clinical outcome of combination therapy of alendronate and silymarin on postmenopausal osteoporotic women compared to the monotherapy of each. Methods: This was prospective, interventional, randomized study. A total of 69 patients were classified into 3 groups: Group1 (n=22) received 70 mg alendronate tablet once weekly for two years, Group 2 (n=23) received 140 mg silymarin capsule three times daily for two years, Group 3 (n=24) received 35 mg alendronate once weekly and 140 mg silymarin three times daily for two years. The bone mineral density of the patients was monitored using DXA scan at 0,1 and 2 years. Results: Silymarin showed improvement in the mean T-scores of spine, femur and wrist after two years of treatment, this improvement was significantly less than in patients treated with alendronate or combined therapy(p spine =0.000 p femur =0.000 p wrist =0.003) where the p value represents the significance difference between the three groups after two years of treatment. Conclusion: To consider Silymarin alone as an efficient medication for postmenopausal osteoporosis, it requires further studies for longer time frames, dose assessment and larger patient groups

show abstract

Section: H G Eltoukhymentioning

confidence: 99%

Untitled

2016

IJPSR

View full text Add to dashboard Cite

show abstract

“…Thus, it is recommended that food and drink other than water should not be taken for 2 hours before and 30 minutes after a dose correspondence: hyo-Kyung han college of Pharmacy, Dongguk University-seoul, Donggukro-32, Ilsan-Donggu, goyang 410-820, republic of Korea Tel +823 1961 5217 Fax +823 1961 5206 email hkhan@dongguk.edu of risedronate. 10 This dosing regimen is very inconvenient for patients, resulting in poor compliance and suboptimal clinical effectiveness of risedronate. In addition, risedronate belongs to Biopharmaceutics Classification System class III (high solubility/low permeability) 11 and its oral bioavailability is very low (1%).…”

Section: Introductionmentioning

confidence: 99%

“…Thus, patients should take it on an empty stomach with water and remain upright for at least 30 minutes after taking the drug. 10,45 Use of chitosan-coated liposomes may prevent the interaction with food because risedronate remains inside the liposomes. Further, chitosan-coated liposomes may reduce esophageal irritation by entrapping the drug inside the liposome, keeping it away from direct contact with the esophagus.…”

mentioning

confidence: 99%

Effective mucoadhesive liposomal delivery system for risedronate: preparation and in vitro/in vivo characterization

Jung

Han

2014

IJN

View full text Add to dashboard Cite

In this work, we aimed to develop chitosan-coated mucoadhesive liposomes containing risedronate to improve intestinal drug absorption. Liposomes containing risedronate were prepared with 1,2-distearoryl-sn-glycero-3-phosphocholine and distearoryl-sn-glycero-3-[phospho-rac-(1-glycerol)] using the freeze-drying method, with subsequent coating of the anionic surfaces of the liposomes with chitosan. The in vitro characteristics of the chitosan-coated liposomes were investigated, including their stability, mucoadhesiveness, and Caco-2 cell permeability. This formulation was stable in simulated gastric and intestinal fluids, with the percentage of drug remaining in the liposomes being more than 90% after 24 hours of incubation. Chitosan-coated liposomes also showed strong mucoadhesive properties, implying potential electrostatic interaction with the mucous layer in the gastrointestinal tract. Compared with the untreated drug, chitosan-coated liposomes significantly enhanced the cellular uptake of risedronate, resulting in an approximately 2.1–2.6-fold increase in Caco-2 cells. Further, the chitosan-coated liposomes increased the oral exposure of risedronate by three-fold in rats. Taken together, the results of this study suggest that chitosan-coated liposomes containing risedronate should be effective for improving the bioavailability of risedronate.

show abstract

“…The most frequently reported side effect attributed to the use of bisphosphonates is upper GI irritation. To date, nonrandomized studies [10][11][12][13] and one randomized, placebo-controlled trial 14 have confirmed the benefit of daily therapy with oral bisphosphonates, including alendronate, in treating CF-related bone loss.…”

mentioning

confidence: 99%

“…8,9 Bisphosphonates belong to a class of compounds that exert a significant inhibitory effect on osteoclasts and are therefore potent antiresorptive agents. 10 They reduce bone turnover, increase bone mineral density (BMD), and decrease fracture risk both at the lumbar spine and the hip. Due to their selectivity in action, they are usually not associated with systemic side effects or serious adverse events.…”

mentioning

confidence: 99%